NEW YORK (GenomeWeb News) – Illumina has appointed Richard Klausner to senior vice president and chief medical officer, where he will lead Illumina's strategies for advancing genomics into clinical medicine and public health.
Previously, Klausner was managing partner of the Column Group, a venture capital firm. He has also served as executive director of the Bill and Melinda Gates Foundation, director of the National Cancer Institute, chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development, and past president of the American Society of Clinical Investigation.
Gregory Lucier has been appointed to the board of directors at RainTree Oncology.
Lucier is CEO and chairman of Life Technologies and recently was elected chairman of the board at Sanford-Burnham Medical Research Institute. He also serves on the boards of CareFusion Corporation, Synthetic Genomics, and Rady Children's Hospital.
SynapDx has appointed Mark DePristo to the post of vice president of informatics. DePristo joins the company from the Broad Institute, where he served as co-director of medical and population genetics. His team at the Broad created the Genome Analysis Toolkit.
In gearing up for the launch of its CLIA-certified next-generation sequencing-based lab and diagnostics platform for personalizing cancer treatments, Basel, Switzerland-based MolecularHealth has appointed a management team to run its newly opened US offices in Woodlands, Texas.
The management team will be headed by Lloyd Everson, who will be CEO of the US division of MolecularHealth. Marc Kerlin will be COO, Philip Watts will be general counsel, and Chet Dye will be chief development officer.
Everson joins MolecularHealth from US Oncology, where he was vice chairman and a member of its board of directors. Kerlin was most recently president and CEO and e+Cancer Care. Watts helped advance the business plan at US Physiatry and was employed at US Oncology for several years in various capacities, including general counsel. Dye was chief development officer at Solis Women's Health and also formerly national VP at US Oncology.
Theradiag this week announced several management changes in line with the strategic reorganization of the company into two divisions following last year's acquisition of microRNA technology firm Prestizia. Specifically, Philippe Lestage will lead Theradiag's In Vitro Diagnostics division while Valery Labonne will lead the company's Theranostics division.
Lestage joins Theradiag from Ortho Clinical Diagnostics, a Johnson & Johnson company, where he most recently held the position of marketing director of transfusion medicine for Europe. As head of the IVD business unit he will be responsible for commercial operations, marketing, and customer service for France and international markets.
Labonne is a former marketing director for Boehringer Ingelheim and co-founder of StarGen Consulting. As head of the Theranostics division he will oversee domestic and international sales and marketing, Theradiag said.
Meantime, Odile Prigneau, previously vice president of marketing and business development at Theradiag, is now general manager of Prestizia, the subsidiary of Theradiag dedicated to microRNAs. Prigneau will retain her business development responsibilities within Theradiag and assist Labonne's marketing staff members in transitioning to their new responsibilities.
Theradiag also said that Eric Sallen, current director of sales, is leaving the company this month.
Agilent this week named Robert Cantrell vice president and treasurer. He replaces Neil Dougherty, who is CFO-designate of the new electronic measurement company to be formed by the separation of Agilent into two publicly traded companies, which was announced last week.
Cantrell was previously operational CFO for the company's electronic measurement business.
Memorial Sloan-Kettering Cancer Center has named three investigators to receive the Paul Marks Prize for Cancer Research, which provides an award of $50,000 to recognize promising investigators aged 45 and under.
The latest winners of the biennial prize are Simon Boulton of Cancer Research UK; Levi Garraway of Dana-Farber Cancer Institute and the Broad Institute; and Duojia Pan of Johns Hopkins University School of Medicine and the Howard Hughes Medical Institute.
Boulton received the award for his efforts to discover novel DNA repair genes and cancer-relevant molecular pathways, Garraway for his studies of genetic changes that can lead to cancers or enable them to develop resistance to targeted therapies, and Pan for his research into the molecular mechanisms that regulate tissue growth in animal development and how defects in those mechanisms can lead to cancer.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.